Clinical Trial Update: ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety of combining zoledronic acid with high hypofractionated radiotherapy in bone metastases due to prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Prostate Adenocarcinoma | Phase 1 | Status: COMPLETED